Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1979 1
2010 1
2011 4
2012 3
2013 4
2014 1
2015 1
2016 5
2017 4
2018 6
2019 6
2020 13
2021 20
2022 14
2023 12
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: galloway jb. Ann Rheum Dis. 2023 Aug;82(8):1059-1067. doi: 10.1136/ard-2023-224049. Epub 2023 May 29. Ann Rheum Dis. 2023. PMID: 37247942 Free PMC article.
Reply.
Bechman K, Galloway JB. Bechman K, et al. Among authors: galloway jb. Arthritis Rheumatol. 2022 Apr;74(4):729. doi: 10.1002/art.42028. Epub 2022 Mar 3. Arthritis Rheumatol. 2022. PMID: 34807511 No abstract available.
Colchicine and the heart: old friends, old foes.
Russell MD, Bukhari M, Shah AM, Galloway JB. Russell MD, et al. Among authors: galloway jb. Rheumatology (Oxford). 2021 May 14;60(5):2035-2036. doi: 10.1093/rheumatology/keab062. Rheumatology (Oxford). 2021. PMID: 33493309 No abstract available.
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Yates M, et al. Among authors: galloway jb. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. Arthritis Rheumatol. 2021. PMID: 33174384
The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know.
Bechman K, Dey M, Yates M, Bukhari M, Winthrop K, Galloway JB. Bechman K, et al. Among authors: galloway jb. J Rheumatol. 2021 Aug;48(8):1201-1204. doi: 10.3899/jrheum.210106. Epub 2021 Jun 1. J Rheumatol. 2021. PMID: 34074678 No abstract available.
The infection risks of JAK inhibition.
Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. Adas MA, et al. Among authors: galloway jb. Expert Rev Clin Immunol. 2022 Mar;18(3):253-261. doi: 10.1080/1744666X.2022.2014323. Epub 2021 Dec 29. Expert Rev Clin Immunol. 2022. PMID: 34860621 Free PMC article.
NEIAA: driving EIA service quality in a shifting clinical landscape.
Ledingham JM, Yates M, Galloway JB. Ledingham JM, et al. Among authors: galloway jb. Rheumatology (Oxford). 2020 Nov 1;59(11):3127-3128. doi: 10.1093/rheumatology/keaa423. Rheumatology (Oxford). 2020. PMID: 32879979 No abstract available.
Delivering future clinical trials in rheumatology.
Galloway JB, Scott DL. Galloway JB, et al. J Rheumatol. 2015 Jan;42(1):18-20. doi: 10.3899/jrheum.141270. J Rheumatol. 2015. PMID: 25554806 Free article. No abstract available.
Biosimilars in rheumatology: out of the laboratory and into practice.
Rutherford AI, Galloway JB. Rutherford AI, et al. Among authors: galloway jb. Expert Rev Clin Immunol. 2016 Jul;12(7):697-9. doi: 10.1080/1744666X.2016.1191946. Epub 2016 Jun 1. Expert Rev Clin Immunol. 2016. PMID: 27195989 No abstract available.
86 results